Luye Pharma GroupFRA:LUP +3.03%47 EV-to-FCF is 6.33 as of Jul. 03, 2026, which is 109% above its 10-year median of 3.03. GuruFocus rates FRA:LUP with a GF Score™ of 47/100 and a GF Value™ of €0.32 (Possible Value Trap). The stock has 5 warning signs investors should review. Among 562 Drug Manufacturers companies, Luye Pharma Group ranks better than 85.94% on this metric.
EV-to-FCF is calculated as enterprise value divided by its free cash flow. As of today, Luye Pharma Group's Enterprise Value is €1,361.8 Mil.
Luye Pharma Group's Free Cash Flow for the trailing twelve months (TTM) ended in Dec. 2025 was €215.3 Mil. Therefore, Luye Pharma Group's EV-to-FCF for today is 6.33.
The historical rank and industry rank for Luye Pharma Group's EV-to-FCF or its related term are showing as below:
FRA:LUP'
s EV-to-FCF Range Over the Past 10 Years
Min: -44.12 Med: 3.03 Max: 76.12
Current: 6.25
During the past 13 years, the highest EV-to-FCF of Luye Pharma Group was 76.12. The lowest was -44.12. And the median was 3.03.
FRA:LUP's EV-to-FCF is ranked better than 85.94% of 562
companies
in the Drug Manufacturers industry
Industry Median: 20.525
vs FRA:LUP: 6.25
EV-to-FCF is a valuation multiple that allows analysts and investors to compare stocks, preferably in the same sector or industry. This important multiple is often used in conjunction with, or as an alternative to, the PE Ratio (TTM) to determine the fair market value of a company.
EV-to-FCF is a valuation multiple that allows analysts and investors to compare stocks, preferably in the same sector or industry. This important multiple is often used in conjunction with, or as an alternative to, the PE Ratio (TTM) to determine the fair market value of a company.
Luye Pharma Group's PE Ratio (TTM) for today is calculated as:
Luye Pharma Group's share price for today is €0.204.
For company reported semi-annually, GuruFocus uses latest annual data as the TTM data. Luye Pharma Group's Earnings per Share (Diluted) for the trailing twelve months (TTM) ended in Dec. 2025 was €0.019.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Enterprise Value is used because it is a more complete measure in reflecting how much an investor pays when buying a company. Free Cash Flow is an important financial metric because it represents the actual amount of cash at a company's disposal. Companies with a low EV-to-FCF ratio, combined with a strong balance sheet are generally considered as undervalued.
Luye Pharma Group EV-to-FCF Related Terms
Luye Pharma Group EV-to-FCF Historical Data
* Premium members only.
The historical data trend for Luye Pharma Group's EV-to-FCF can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
For the Drug Manufacturers - Specialty & Generic subindustry, Luye Pharma Group's EV-to-FCF, along with its competitors' market caps and EV-to-FCF data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Luye Pharma Group EV-to-FCF vs Drug Manufacturers Industry
For the Drug Manufacturers industry and Healthcare sector, Luye Pharma Group's EV-to-FCF distribution charts can be found below:
* The bar in red indicates where Luye Pharma Group's EV-to-FCF falls into.
Luye Pharma Group's current Enterprise Value is €1,361.8 Mil.
For company reported semi-annually, GuruFocus uses latest annual data as the TTM data. Luye Pharma Group's Free Cash Flow for the trailing twelve months (TTM) ended in Dec. 2025 was €215.3 Mil.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Luye Pharma Group (FRA:LUP) has a EV-to-FCF of 6.33 as of Jul. 03, 2026. EV to FCF ratio is the company's enterprise value divided by free cash flow. View historical data on Luye Pharma Group and its competitors. This is 109% above median its historical median of 3.03. According to the industry distribution chart, Luye Pharma Group ranks #79 out of 562 companies in the Drug Manufacturers industry, placing it in the top 14.1%.
Is Luye Pharma Group's EV-to-FCF too high?
Luye Pharma Group's current EV-to-FCF of 6.33 is 109% above median its 10-year median of 3.03. The Drug Manufacturers industry median EV-to-FCF is 20.53. Luye Pharma Group's value of 6.33 is 69.2% below this industry median. Based on the distribution chart, Luye Pharma Group ranks #79 out of 562 companies in the Drug Manufacturers industry, which is in the top quartile — a strong position relative to peers. Overall, Luye Pharma Group has a GF Score™ of 47/100 and is considered Possible Value Trap, reflecting its overall financial health beyond just this single metric.
How does Luye Pharma Group's EV-to-FCF compare to ZTS and UTHR?
According to the Drug Manufacturers industry distribution chart, Luye Pharma Group ranks #79 out of 562 companies for EV-to-FCF. This places Luye Pharma Group in the top 14% of its industry — outperforming the majority of peers. The industry median EV-to-FCF is 20.53. Luye Pharma Group's value of 6.33 is 69.2% below this benchmark. While the company's 10-year median is 3.03 vs. the industry median of 20.53, Luye Pharma Group has consistently been below the industry average. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good EV-to-FCF for a Drug Manufacturers company?
The median EV-to-FCF among Drug Manufacturers companies is 20.53, based on 562 companies in the industry. Companies in the top quartile (top 25%) have a EV-to-FCF significantly above this median, while those in the bottom quartile fall well below. However, EV-to-FCF should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Luye Pharma Group's current EV-to-FCF of 6.33 is 69.2% below the industry median. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high EV-to-FCF mean?
A high EV-to-FCF can signal that a stock is expensive relative to its fundamentals. EV to FCF ratio is the company's enterprise value divided by free cash flow. View historical data on Luye Pharma Group and its competitors. For the Drug Manufacturers industry, the median EV-to-FCF is 20.53 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. Luye Pharma Group's current EV-to-FCF is 6.33, which is 109% above median its own 10-year median of 3.03. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Luye Pharma Group stock overvalued right now?
Based on GuruFocus' analysis, Luye Pharma Group (FRA:LUP) is currently considered Possible Value Trap. The stock's GF Value™ is €0.32, compared to a current price of €0.20 — trading 36.3% below its estimated fair value. The current EV-to-FCF is 6.33, which is 109% above median its 10-year median of 3.03 and 69.2% below the Drug Manufacturers industry median of 20.53. Luye Pharma Group's overall GF Score™ is 47/100 with 5 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is EV-to-FCF calculated?
EV-to-FCF is calculated from a company's financial statements. For Luye Pharma Group (FRA:LUP), the current EV-to-FCF is 6.33 as of Jul. 03, 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Is Luye Pharma Group (FRA:LUP) Overvalued in 2026?
Based on GuruFocus' analysis, Luye Pharma Group stock appears to be undervalued.
The current stock price of €0.20 is trading 36.3% below its estimated GF Value™ of €0.32.
GuruFocus considers Luye Pharma Group to be Possible Value Trap.
Key valuation signals for FRA:LUP:
EV-to-FCF: 6.33 (109% above median its 10-year median of 3.03)
GF Value™: €0.32 vs. price of €0.20 (36.3% below fair value)
Industry Position: 69.2% below the Drug Manufacturers median (#79 of 562)
No single metric tells the full story. See the FRA:LUP stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.
Luye Pharma Group Ltd is a China-based drug manufacturer that focuses on development, production, marketing and sale of pharmaceutical products. The company develops drugs related to diagnosing and treating cancer, the cardiovascular system, the alimentary tract, and the central nervous system. The company develops drugs for world-wide use in Asia, Europe, and the United States. The Group organizes its business segments by type of products. Oncology drugs, which derives maximum revenue; Cardiovascular system drugs; Alimentary tract and metabolism drugs; Central nervous system drugs; and others. Geographically, the group derives maximum revenue from Chinese Mainland, while it also has its presence in Asia (other than the Chinese mainland), European Union, and Other countries.
47GF Score
Get the complete analysis for FRA:LUP
EV-to-FCF is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
FRA:LUP has been successfully added to your 
